Total Holdings
72
As of Oct 4, 2026
Franklin Genomic Advancements ETF
HELXBATSFranklin TempletonEquity
$41.24Today:- (-)1Y +28.52%
As of Oct 16, 2026 close
- Assets (AUM)
- $32.89M
- Expense ratio
- 0.50%
- Dividend yield
- 0.34%
- Holdings
- 72
- 52-week range
- $31.24$45.58
- Volume (live)
- -
- Avg. volume (3M)
- 10.29K
HELX ETF Holdings: Franklin Genomic Advancements ETF
Every listed position with its portfolio weight, plus sector breakdown and geographic exposure for this Equity ETF. Analyze fund diversification and concentration.
Top 10 Holdings
51.8%
Share of fund assets
Assets (AUM)
$32.89M
Total fund assets
Expense Ratio
0.50%
Annual management fee
Portfolio Allocations
Distribution breakdown by sector, asset type, and geographic region. Understand the fund's diversification strategy across markets and asset classes.
Loading chart...
Top 51 of 72 HELX Holdings by Portfolio Weight
Holdings as of Oct 4, 2026. Ticker, name, asset type and portfolio weight for each position. Fund disclosures available to us list the largest 51 positions.
Scroll to see more
| # | Symbol | Name | Type | Weight |
|---|---|---|---|---|
| 1 |  | Natera, Inc. | Stock | 10.26% |
| 2 |  | Guardant Health, Inc | Stock | 10.14% |
| 3 |  | Krystal Biotech, Inc | Stock | 5.46% |
| 4 |  | Twist Bioscience Corporation | Stock | 5.20% |
| 5 |  | Adaptive Biotechnologies Corporation | Stock | 4.80% |
| 6 |  | Ligand Pharmaceuticals Incorporated | Stock | 4.39% |
| 7 |  | BridgeBio Pharma, Inc | Stock | 3.06% |
| 8 |  | Travere Therapeutics Inc | Stock | 3.02% |
| 9 |  | Medpace Holdings, Inc | Stock | 2.80% |
| 10 |  | Vertex Pharmaceuticals Incorporated | Stock | 2.71% |
| 11 |  | Corteva, Inc | Stock | 2.60% |
| 12 |  | United Therapeutics Corporation | Stock | 2.52% |
| 13 |  | Eli Lilly and Company | Stock | 2.33% |
| 14 |  | Regeneron Pharmaceuticals, Inc | Stock | 2.12% |
| 15 |  | GRAIL, Inc. | Stock | 2.08% |
| 16 |  | Tempus AI, Inc. | Stock | 2.04% |
| 17 | VYLR | Vylor, Inc. | Stock | 2.00% |
| 18 |  | Repligen Corporation | Stock | 1.99% |
| 19 |  | CareDx, Inc. | Stock | 1.75% |
| 20 | EBR:ARGX | Argen-X | Stock | 1.67% |
| 21 |  | Neurocrine Biosciences, Inc | Stock | 1.56% |
| 22 |  | Charles River Laboratories International, Inc. | Stock | 1.47% |
| 23 |  | Jazz Pharmaceuticals plc | Stock | 1.45% |
| 24 |  | 10x Genomics, Inc. | Stock | 1.43% |
| 25 |  | BioNTech SE | Stock | 1.21% |
| 26 |  | Praxis Precision Medicines, Inc | Stock | 1.14% |
| 27 |  | PTC Therapeutics, Inc | Stock | 1.12% |
| 28 |  | IQVIA Holdings Inc | Stock | 1.11% |
| 29 |  | Stoke Therapeutics, Inc | Stock | 1.09% |
| 30 |  | Insmed Incorporated | Stock | 1.04% |
| 31 |  | Revolution Medicines, Inc | Stock | 1.01% |
| 32 |  | Royalty Pharma plc | Stock | 0.98% |
| 33 |  | Kiniksa Pharmaceuticals Ltd | Stock | 0.96% |
| 34 | KO:207940 | Samsung Biologics Co Ltd | Stock | 0.94% |
| 35 |  | Veracyte, Inc | Stock | 0.93% |
| 36 |  | Thermo Fisher Scientific Inc | Stock | 0.92% |
| 37 |  | CRISPR Therapeutics AG | Stock | 0.89% |
| 38 |  | Hinge Health, Inc. | Stock | 0.89% |
| 39 | ETR:SRT3 | Sartorius Aktiengesellschaft | Stock | 0.85% |
| 40 |  | AnaptysBio, Inc | Stock | 0.80% |
| 41 |  | Eton Pharmaceuticals Inc | Stock | 0.69% |
| 42 |  | Axsome Therapeutics, Inc | Stock | 0.65% |
| 43 |  | Agilent Technologies, Inc | Stock | 0.63% |
| 44 |  | First Tracks Biotherapeutics | Stock | 0.62% |
| 45 |  | Cadence Design Systems, Inc | Stock | 0.60% |
| 46 |  | Beam Therapeutics Inc | Stock | 0.60% |
| 47 |  | Genmab A/S | Stock | 0.56% |
| 48 |  | Roivant Sciences Ltd | Stock | 0.52% |
| 49 | LSE:AZN | AstraZeneca PLC | Stock | 0.50% |
| 50 |  | Mineralys Therapeutics Inc. Common Stock | Stock | 0.50% |
| 51 |  | QIAGEN N.V | Stock | 0.50% |
Source: Fund holdings disclosures. Data as of Oct 4, 2026. Data sources and methodology
Frequently Asked Questions About Franklin Genomic Advancements ETF Holdings
What are the top holdings in HELX?
As of Oct 4, 2026, Franklin Genomic Advancements ETF (HELX) holds 72 securities. The largest are Natera, Inc. (10.26%), Guardant Health, Inc (10.14%), Krystal Biotech, Inc (5.46%). The holdings table lists each position by portfolio weight with its ticker, name and asset type.
How concentrated is HELX's portfolio?
As of Oct 4, 2026, the 10 largest positions make up 51.8% of HELX's assets. A concentrated portfolio has fewer large positions with higher individual weights, while a diversified portfolio distributes holdings more evenly.
What is HELX's sector allocation?
The Sector Allocation chart shows how HELX distributes investments across different industries like Technology, Healthcare, Financials, and more. This sector exposure helps understand the fund's industry diversification strategy.
What countries does HELX invest in?
HELX's geographic exposure is shown in the Countries tab under Portfolio Allocations. This reveals the fund's international diversification and exposure to different regions and global markets.
How diversified is HELX ETF?
HELX's diversification can be assessed by reviewing its 72 holdings (as of Oct 4, 2026), sector allocation, and geographic exposure. A well-diversified ETF spreads investments across multiple securities, sectors, and regions to reduce concentration risk.